Chapter 35: Psoriasis and Related Disorders

Molecular genetics

35.2 Chapter 35: Psoriasis and Related Disorders

Infection

Medications

Alcohol misuse

Psychological distress
References 35.3

Sunshine

Physical trauma

Pathogenic mechanisms

Histopathology
2 Kogoj E. Un cas de maladie de Hallepeau. Acta Derm Venereol (Stockh) 1927;8:1–12.

History
3 Reich A, Hrehörperow E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010;90:257–63.

Presentation
2 Woronoff DI. Die periphere Veranderungen der Haut, um die Effloreszenzen der Psoriasis vulgaris und Syphilis corrosiva. Derm Wsh 1926;82:249–53.

Scalp psoriasis

Follicular psoriasis

Seborrheic psoriasis (sebopsoriasis)

Flexural psoriasis (inverse psoriasis)

Genital psoriasis
35.4 Chapter 35: Psoriasis and Related Disorders

Non-pustular palmoplantar psoriasis

Nail psoriasis

Mucosal lesions

Ocular lesions

Acute guttate psoriasis

HIV-induced or exacerbated psoriasis

Classification of severity

Complications and co-morbidities

Immune-mediated inflammatory diseases

Psychological distress

Cancer

Metabolic syndrome and its components

### Cardiovascular disease


### Hepatobiliary disease


### Others


### Disease course and prognosis


### Investigations


Management


Topical treatment

Topical corticosteroids

Vitamin D analogues

35.11

Dithranol
Topical retinoids


Topical calcineurin inhibitors


Narrow-band UVB

PUVA phototherapmy


Ciclosporin


Fumaric acid esters


Hydroxyurea


Apremilast


Tofacitinib


Ponesimod


Biological therapy


35.12 Chapter 35: Psoriasis and Related Disorders


Pustular psoriasis


Generalized pustular psoriasis


Age at onset


Gender


Associated diseases


Predisposing factors


Genetic and environmental risk factors


Acute generalized pustular psoriasis (von Zumbusch)


Subacute annular generalized pustular psoriasis


Acute generalized pustular psoriasis of pregnancy (impetigo herpetiformis)


Infantile and juvenile generalized pustular psoriasis


References 35.13
35.14 Chapter 35: Psoriasis and Related Disorders

Systemic therapy

Palmoplantar pustulosis
4 Shukuya R, Hasegawa T, Niwa Y, et al. Histopathology of pustulosis palmaris et plantaris have increased IL-17 and IL-22 levels both in the lesion and serum. J Invest Dermatol 2010;130:2010–
6 Induction or exacerbation of psoriatic arthritis may be improved after cessation of smoking. J Am Acad Dermatol 2006;54:737–8.

**Genetics**


**Clinical features**


**Pustular bacterid (of Andrews)**


**Classification of severity**

Clinical features

Management

Psoriatic arthritis

Incidence and prevalence

Age at onset and associated diseases

Genetics and pathophysiology

Causes

Pathophysiology

Clinical features

Classification of severity
2 Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARC), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy–Fatigue (FACT–F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CDAI). Arthritis Care Res (Hoboken) 2011;63 Suppl. 11:564–85.
Investigations